Intended for non-insulin-using individuals aged 18 and older, the Libre Rio system is said to be the first over-the-counter CGM system in the US with a glucose measurement range of 40mg/dL-400mg/dL.

Abbott ABT announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are based on Abbott’s own Freestyle Libre continuous glucose ...

Abbott gets FDA clearance for over-the-counter continuous glucose monitors. The Libre Rio is designed for Type 2 diabetics who don’t use insulin, while the Lingo is for people who want to learn ...

Earlier, in June 2024, the U.S. FDA cleared Abbott’s – Libre Rio and Lingo – new over-the-counter glucose monitoring devices. This should also aid the overall diabetes portfolio sales.

In June, Abbott Laboratories announced that the U.S. Food and Drug Administration (FDA) had cleared the Libre Rio, a new over-the-counter (OTC) CGM option for type 2 diabetes patients who do not ...

In 2024, Abbott obtained FDA approvals for two new over-the-counter CGMs called Lingo and Libre Rio, which are based on Libre’s technology. The technology is now used by more than 6 million ...

The Food and Drug Administration (FDA) has cleared Abbott’s Lingo ™ and Libre Rio ... Libre Rio Continuous Glucose Monitoring System. 510(k) Premarket Notification. K233861.

Abbott's new Libre Rio and Lingo wearable sensors are aimed at the growing health and wellness market, as well as people with Type 2 diabetes that are not taking insulin.

Libre Rio Libre Rio will be Abbott’s first over-the-counter CGM system for people with diabetes in the U.S. It is designed for people ages 18 and older with Type 2 diabetes who do not use ...

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, ... Lingo and Libre Rio, another of Abbott's devices, ...

The pairing of Abbott's leading FreeStyle Libre technology with Medtronic's AID algorithms could enable automatic insulin adjustment for Type 1 and Type 2 diabetics to keep glucose in range.